Novel antigens of CAR T cell therapy: New roads; old destination

Novel antigens of CAR T cell therapy: New roads; old destination

Chimeric antigen receptor T cell (CAR-T) therapy has so far proved itself as a reliable therapeutic option for the treatment of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and mantle cell lymphoma (MCL). However...

Full description

Bibliographic Details
Main Authors:	Pooria Safarzadeh Kozani, Pouya Safarzadeh Kozani, Fatemeh Rahbarizadeh
Format:	Article
Language:	English
Published:	Elsevier 2021-07-01
Series:	Translational Oncology
Subjects:	Cancer immunotherapy Adoptive cell therapy CasMab Tumor-associated antigens Chimeric antigen receptor
Online Access:	http://www.sciencedirect.com/science/article/pii/S1936523321000711

Similar Items

Strategies for Dodging the Obstacles in CAR T Cell Therapy
by: Pooria Safarzadeh Kozani, et al.
Published: (2021-04-01)

Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward
by: Pouya Safarzadeh Kozani, et al.
Published: (2021-10-01)

CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?
by: Pouya Safarzadeh Kozani, et al.
Published: (2021-10-01)

Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
by: Pouya Safarzadeh Kozani, et al.
Published: (2022-05-01)

CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer
by: Fatemeh Nasiri, et al.
Published: (2023-12-01)

T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts
by: Fatemeh Nasiri, et al.
Published: (2023-02-01)

Podoplanin as an Attractive Target of CAR T Cell Therapy
by: Masazumi Waseda, et al.
Published: (2020-08-01)

CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
by: Fatemeh Nasiri, et al.
Published: (2022-11-01)

Nanobody-based CAR-T cells for cancer immunotherapy
by: Pouya Safarzadeh Kozani, et al.
Published: (2022-04-01)

Foreign or Domestic CARs: Receptor Ligands as Antigen-Binding Domains
by: Donald R. Shaffer, et al.
Published: (2014-01-01)

Characterization of novel CD19-specific VHHs isolated from a camelid immune library by phage display
by: Mahmoud Ganji, et al.
Published: (2023-12-01)

Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies
by: Hamed Dabiri, et al.
Published: (2023-07-01)

Spinoculation and retronectin highly enhance the gene transduction efficiency of Mucin-1-specific chimeric antigen receptor (CAR) in human primary T cells
by: Alireza Rajabzadeh, et al.
Published: (2021-11-01)

CAR T Cell Therapy: A Versatile Living Drug
by: Rodrigo C. De Marco, et al.
Published: (2023-03-01)

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)
by: Astero Klampatsa, et al.
Published: (2017-09-01)

Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9
by: Jiangtao Ren, et al.
Published: (2017-04-01)

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors
by: Francesco Boccalatte, et al.
Published: (2022-10-01)

Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead
by: Tahereh Soltantoyeh, et al.
Published: (2021-06-01)

Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system
by: Abbas Hajifathali, et al.
Published: (2024-01-01)

Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma
by: Karin Teppert, et al.
Published: (2023-10-01)

Therapeutic Applications: Natural Killer Cells
by: Preeti Sharma, et al.
Published: (2018-02-01)

Antigen-specific T cell activation independently of the MHC: chimeric antigen receptor (CAR)-redirected T cells.
by: Hinrich eAbken, et al.
Published: (2013-11-01)

Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions
by: Peng Zhang, et al.
Published: (2022-07-01)

T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy
by: Elien De Bousser, et al.
Published: (2021-12-01)

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
by: Stefan Stoiber, et al.
Published: (2019-05-01)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
by: Wenwen Wei, et al.
Published: (2022-11-01)

Chimeric antigen receptor T-cell therapy in hematopoietic and nonhematopoietic malignancies
by: Faizan Ahmad
Published: (2020-01-01)

The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies
by: Andriy Zhylko, et al.
Published: (2020-07-01)

Augmenting human gamma delta lymphocytes for cancer therapy with chimeric antigen receptors
by: Gabrielle M. Ferry, et al.
Published: (2022-03-01)

CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors
by: Vanesa Alonso-Camino, et al.
Published: (2013-01-01)

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
by: Michael A. Morgan, et al.
Published: (2020-08-01)

The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy
by: Dongfang Liu, et al.
Published: (2020-08-01)

Seatbelts in CAR therapy: How Safe Are CARS?
by: Kentaro Minagawa, et al.
Published: (2015-05-01)

Characterization of CAR T Cells Manufactured Using Genetically Engineered Artificial Antigen Presenting Cells
by: Ali Sayadmanesh, et al.
Published: (2023-10-01)

Advances in Universal CAR-T Cell Therapy
by: Haolong Lin, et al.
Published: (2021-10-01)

Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing
by: Tiziano Ingegnere, et al.
Published: (2019-04-01)

Humanized single-domain antibody targeting HER2 enhances function of chimeric antigen receptor T cells
by: Rui Zheng, et al.
Published: (2023-11-01)

The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: Moderate is better
by: Rui Mao, et al.
Published: (2022-10-01)

Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an “Off-the-Shelf Immunotherapy” for Improvement in Cancer Treatment
by: Olaf Oberschmidt, et al.
Published: (2017-06-01)

Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges
by: Ensaf M. Al-Hujaily, et al.
Published: (2022-11-01)